BioNexus Gene Lab
BGLC
$4.46
Share price
-1.98%
Change (1 day)
810.20%
Change (1 year)
Categories
Operating Margin for BioNexus Gene Lab (BGLC)
Operating Margin as of July 2025 (TTM): -23.03%
According to BioNexus Gene Lab's latest financial reports and stock price the company's current Operating Margin is -23.03%. At the end of 2024 the company had an Operating Margin of -16.55%.
Operating Margin history for BioNexus Gene Lab from 2019 to 2025
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2024 | -16.55% | -37.66% |
| 2023 | -26.54% | 896.28% |
| 2022 | -2.66% | -133.72% |
| 2021 | 7.90% | -29.35% |
| 2020 | 11.18% | -105.15% |
| 2019 | -217.17% | -869.78% |
| 2018 | 28.21% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin differencediff. | Country |
|---|---|---|---|
 ORIC Pharmaceuticals
ORIC | 0.00% | N/A | 🇺🇸 USA |
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.